S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Tang
    Tang
  8. Clarkson
    Clarkson
  9. Janjigian
    Janjigian
  10. Marghoob
    Marghoob

Groups

  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Sloan Kettering Institute Faculty (47)
  10. Thoracic Oncology (45)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (254)
  3. Book Section (20)
  4. Review (15)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (3)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (633)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Resection of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas: A Nordic multicenter study
    Meeting Abstract

    Galleberg, R. B.; Knigge, U.; Janson, E. T.; Vestermark, L. W.; Haugvik, S. P.; Ladekarl, M.; Langer, S. W.; Grønbæk, H.; Österlund, P.; Hjortland, G.; more...
    Neuroendocrinology (2017)

    Fulltext@MSK | Save
  • Lanreotide autogel/depot (LAN) in lung neuroendocrine tumours (NETs): The randomized, double-blind, placebo (PBO)-controlled, international phase 3 SPINET study
    Meeting Abstract

    Reidy-Lagunes, D.; Kulke, M. H.; Wolin, E. M.; Singh, S.; Ferone, D.; Hörsch, D.; Mirakhur, B.; Hoffmanns, P.; Houchard, A.; Caplin, M.; more...
    Neuroendocrinology (2017)

    Fulltext@MSK | Save
  • Clinical nomogram development and predictive utility for appendiceal and colorectal NETs
    Meeting Abstract

    Kolasińska-Ćwikła, A.; Ćwikła, J.; Kidd, M.; Bodei, L.; Lewczuk, A.; Drozdov, I.; Modlin, I.
    Neuroendocrinology (2017)

    Fulltext@MSK | Save
  • Anti-CTLA-4 checkpoint inhibitormediated anticancer immunity relies on tumor-intrinsic RIG-I signaling
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Bek, S.; Schmickl, M.; Steiger, K.; Koenig, P. A.; Ruland, J.; van den Brink, M. R. M.; Peschel, C.; Haas, T.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • Nivolumab ± ipilimumab in patients (pts) with advanced (adv) / metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study
    Meeting Abstract

    Jaeger, D.; Janjigian, Y. Y.; Ott, P. A.; Calvo, E.; Kim, J. W.; Ascierto, P. A.; Sharma, P.; Peltola, K.; Evans, J.; de Braud, F.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • Evaluation of nivolumab (nivo) alone and in combination with ipilimumab (ipi) in patients (pts) with advanced (adv) small-cell lung cancer (SCLC): First report of a randomized expansion cohort from the CheckMate 032 trial
    Meeting Abstract

    Atmaca, A.; Hellmann, M. D.; Ott, P. A.; Zugazagoitia, J.; Ready, N.; Hann, C. L.; De Braud, F.; Antonia, S.; Ascierto, P.; Moreno, V.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • Atezolizumab as 1L therapy for advanced NSCLC in PD-L1-selected patients: Updated ORR, PFS and OS data from the BIRCH study
    Meeting Abstract

    Eberhardt, W. E. E.; Garassino, M. C.; Rizvi, N. A.; Jänne, P. A.; Christoph, D.; Peters, S.; Toh, C. K.; Kurata, T.; Costa, E. C.; Koczywas, M.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients
    Meeting Abstract

    Griesinger, F.; Kowanetz, M.; Zou, W.; Shames, D. S.; Cummings, C. A.; Rizvi, N. A.; Spira, A.; Frampton, G.; Leveque, V.; Flynn, S.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: Full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial
    Meeting Abstract

    Jäger, U.; Engert, A.; Fanale, M.; Santoro, A.; Armand, P.; Ansell, S.; Zinzani, P. L.; Timmerman, J. M.; Collins, G. P.; Ramchandren, R.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response
    Meeting Abstract

    Liedtke, M.; Comenzo, R. L.; Landau, H.; Sanchorawala, V.; Weiss, B. M.; Zonder, J. A.; Schönland, S. O.; Walling, J.; Kinney, G. G.; Koller, M.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save